Table 1.
Phytochemical | Cancer | Interventions | Effect | References |
---|---|---|---|---|
Allium sativum | Colorectal, liver, and pancreatic cancer patients Colorectal ademas |
500 mg of aged garlic extract (GE) in 4 capsules for 12 weeks 2.4 mL GE in 3 capsules twice a day for 1 year |
Natural killer (NK) cells increased in number and activity. Reduced size and number of colon adenomas. |
[40] [41] |
Camptothecin (Ct) | Patients with refractory cancer Primary/metastatic lung cancer patients |
Ct: 3 weeks drug-1-week rest; Nitro-Ct: 5 day drug- 2 days rest 6.7–26.6 µg/kg of Ct in the form of aerosolized liposomes were given 5 days a week for 6 weeks, followed by a gap of 2 weeks. |
Both the compounds showed tumor regression in patients with breast cancer, prostate cancer, and melanomas. 3 lung patients stabilized upon dosage. |
[42] [43] |
Curcumin | Urinary bladder cancer, uterine cervical neoplasm, and intestinal metaplasia Advanced pancreatic cancer |
500 mg/day, orally, for 3 months Dosage was 8 g/day for one month |
Improvement in 1 out of every 2 patients with bladder cancer and 1 out of 6 patients with intestinal Metaplasia, and 1 out of 4 patients with uterine cervical neoplasm. Study was conducted on 21 patients, of whom 1 had stable disease for >18 months and 1 had tumor reversion. |
[44] [45] |
Green tea | Patients with high-grade prostate intraepithelial neoplasia Patients with adenocarcinoma of the prostate Esophageal cancer Patients with colon, rectum and pancreas cancer |
Green tea catechins (600 mg) were given daily, orally, for one year Tea consumption as a daily routine Usual green tea consumption Non-regular tea consumption |
Improved quality of life Risk declination of prostate cancer with increased consumption of green tea. Reduced risk of Esophageal cancer. Inverse relation was associated with cancer and green tea consumption. |
[46] [47] [48] [49] |
Panax ginseng | Patients with cancer of uterine, ovary, rectum, stomach, etc | 3000 mg/day of the heat-processed ginseng for 12 weeks | Improvement of mental and physical functioning, and hence improved quality of life. | [50] |
Isoflavones | Prostate cancer | (60 mg) daily for 12 months | Reducing prostate cancer incidence for patients aged 65 or more. | [51] |
Synthetic genistein | Prostate cancer | 54 patients with localized prostate cancer. (30 mg) daily for 3–6 weeks | Decreasing level of serum prostate specific antigen (PSA). | [52] |
Soy isoflavone | Prostate cancer | 86 patients with localized prostate cancer. (80 mg total isoflavones, 51 mg aglucon units) daily for 6 weeks | No significant change in serum hormone levels, total cholesterol, or PSA. | [53] |
Flavonoid mixture | Colorectal cancer | (20 mg apigenin and 20 mg EGCG) for 3–4 years. 87 patients with resected colorectal cancer or polypectomy | Reducing the recurrence rate of colon neoplasia in patients with resected colon cancer. | [54] |
Isoflavones and curcumin | Prostate cancer | Isoflavones (40 mg) and curcumin (100 mg) daily for 6 months | decreasing level of serum PSA. | [55] |